Noxopharm is an Australian clinical-stage drug development company listed on the Australian Securities Exchange (ASX: NOX) since 2016. It is the third of four public companies founded by one of Australia's pioneering cancer researchers, Dr Graham Kelly. The fourth public company founded by Dr Kelly is Nyrada, Inc. (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases, listed on the ASX since January 2020. Pharmorage is a privately held, fully owned subsidiary of Noxopharm.
Noxopharm's lead drug candidate, Veyonda® (also known as NOX66), is being developed as a treatment for various cancers and has already advanced to phase 2 clinical trials. It also is being investigated as a treatment for septic shock.
Veyonda® is currently not approved in Australia or any other country